NSCLC NSCLC, C-CAT, driver gene
Conditions
Interventions
None listed
Sponsors
Yokochi Yuya
Eligibility
Inclusion criteria
Inclusion criteria: Adult (aged 15 years or more) patients with histologically or cytologically confirmed NSCLC
Exclusion criteria
Exclusion criteria: 1. Patients who have already been confirmed to have a drug-treatable mutation/translocation by the end of standard therapy 2. Patients who received targeted therapy against driver genes before finishing standard therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Among patients with NSCLC diagnosed with wild type (WT) who have completed (or are expected to complete) standard therapy and who underwent comprehensive genomic profiling (CGP) testing, the proportion of patients diagnosed with a drug-treatable mutation by CGP testing ratio Among patients with NSCLC diagnosed with WT who have completed (or are expected to complete) standard therapy and who underwent comprehensive genomic profiling (CGP) testing, the proportion of patients diagnosed with a drug-treatable mutation by CGP testing , percentage by year | — |
Secondary
| Measure | Time frame |
|---|---|
| Describe the characteristics of NSCLC patients with delayed detection of drug-treatable genetic mutations Describe the degree of delay in NSCLC patients with delayed detection of drug-treatable genetic mutations Describe treatment patterns for NSCLC patients with delayed detection of drug-treatable genetic mutations Describe the frequency of delayed detection of drug-treatable genetic mutations by site type Patient baseline characteristics (gender, age, family history, etc.) Time from start of first-line therapy to detection of a drug-treatable mutation Treatment patterns for NSCLC patients with drug-treatable mutations Number and proportion of regimens in each line of treatment Duration of each line of therapy Percentage of patients diagnosed with a drug-treatable mutation by CGP testing, by facility type (size, academic/community, etc.) | — |
Contacts
Public ContactDirect Novartis
Novartis Pharma K.K.
Outcome results
None listed